Company profile for Immuneering Corporation

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a di...
Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. Immuneering’s technologies have proven exceptionally rapid and capital-efficient in creating its pipeline.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
245 Main St, Second Floor Cambridge, MA 02142
Telephone
Telephone
(617) 500-8080
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/25/3194273/0/en/Immuneering-to-Present-at-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186758/0/en/Immuneering-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-and-Clinical-Updates.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180862/0/en/Immuneering-to-Report-Third-Quarter-2025-Financial-Results-and-Provide-New-Clinical-Case-Studies-on-Wednesday-November-12-2025.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/09/26/3157242/0/en/Immuneering-to-Discuss-Recently-Announced-Overall-Survival-Data-from-Phase-2a-Clinical-Trial-of-Atebimetinib-mGnP-in-First-Line-Pancreatic-Cancer-Patients-on-Monday-September-29-20.html

GLOBENEWSWIRE
26 Sep 2025

https://www.biospace.com/drug-development/immuneering-asset-nearly-doubles-overall-survival-in-pancreatic-cancer-after-9-months

BIOSPACE
25 Sep 2025

https://www.globenewswire.com/news-release/2025/09/25/3155961/0/en/Immuneering-Announces-Pricing-of-175-Million-Underwritten-Public-Offering-of-Class-A-Common-Stock-and-Concurrent-25-Million-Private-Placement-of-Class-A-Common-Stock-to-Sanofi.html

GLOBENEWSWIRE
25 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty